These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27029063)

  • 61. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC).
    Qi WX; Zhang Q; Li P; Zhang XM; Zhang GY; Wu B; Lu JJ; Jiang GL; Fu S
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1361-7. PubMed ID: 27008005
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lymphocyte Subsets in a Population of Nonfrail Elderly Individuals.
    Valdiglesias V; Sánchez-Flores M; Maseda A; Marcos-Pérez D; Millán-Calenti JC; Pásaro E; Lorenzo-López L; Laffon B
    J Toxicol Environ Health A; 2015; 78(13-14):790-804. PubMed ID: 26167746
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relationship between sleep disorders and lymphocyte subsets and cytokines in patients with lung cancer.
    Wang Y; Cheng XJ; Yin AH; Cao Y; Zhao ZG; Zhang HJ; Liu DX; Zhang Y; Liu ZX; Lu Y; Jia JC; Liu JT; Pan F
    J Biol Regul Homeost Agents; 2018; 32(5):1231-1237. PubMed ID: 30334418
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature.
    Jingu K; Hasegawa A; Mizo JE; Bessho H; Morikawa T; Tsuji H; Tsujii H; Kamada T
    Radiat Oncol; 2010 Oct; 5():89. PubMed ID: 20920325
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of hormone therapy on immune response in patients with prostatic cancer.
    Guinan PD; Ablin RJ; Nourkayhan S; Bruns GR; Bush IM
    Urology; 1975 Dec; 6(6):693-6. PubMed ID: 1202718
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The risk of subsequent primary cancer after radiotherapy of localised prostate cancer with carbon ions may be reduced compared to treatment with photons].
    Kraus KM; Combs SE
    Strahlenther Onkol; 2019 Nov; 195(11):1033-1035. PubMed ID: 31420708
    [No Abstract]   [Full Text] [Related]  

  • 70. Should we expand the carbon ion footprint of prostate cancer?
    Catton CN; Shultz DB
    Lancet Oncol; 2019 May; 20(5):608-609. PubMed ID: 30885459
    [No Abstract]   [Full Text] [Related]  

  • 71. Key considerations when reviewing subsequent primary cancers following radiotherapy.
    Kishan AU; Wang C; Steinberg ML; Spratt DE
    Lancet Oncol; 2019 Jun; 20(6):e291. PubMed ID: 31162098
    [No Abstract]   [Full Text] [Related]  

  • 72. Key considerations when reviewing subsequent primary cancers following radiotherapy - Authors' reply.
    Mohamad O; Tabuchi T; Morishima T; Makishima H; Miyashiro I; Tsuji H
    Lancet Oncol; 2019 Jun; 20(6):e292. PubMed ID: 31162099
    [No Abstract]   [Full Text] [Related]  

  • 73. Correction to: Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer.
    Takakusagi Y; Katoh H; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Kamada T
    Radiat Oncol; 2022 May; 17(1):101. PubMed ID: 35606764
    [No Abstract]   [Full Text] [Related]  

  • 74. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.
    Eckert F; Schaedle P; Zips D; Schmid-Horch B; Rammensee HG; Gani C; Gouttefangeas C
    Oncoimmunology; 2018; 7(11):e1496881. PubMed ID: 30393582
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients.
    Sage EK; Schmid TE; Geinitz H; Gehrmann M; Sedelmayr M; Duma MN; Combs SE; Multhoff G
    Strahlenther Onkol; 2017 Aug; 193(8):648-655. PubMed ID: 28500490
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
    Chen J; Yu F; He G; Hao W; Hu W
    BMC Cancer; 2024 Feb; 24(1):254. PubMed ID: 38395827
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Correlation Between Low-Dose Radiotherapy Area of the Mediastinum and CD8+T Cells and the Efficacy of Radiotherapy for Non-Small Cell Lung Cancer.
    Wang H; Li Y; Hu P; Zhang J
    Cancer Manag Res; 2024; 16():23-35. PubMed ID: 38230351
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Relationship Between Lymphocyte Subtypes with Clinicopathological Features and Prognosis of Prostate Cancer in Patients Undergoing Radical Prostatectomy.
    Sendogan F; Turan T; Erman H; Danacioglu YO; Isman FK; Atis RG; Silay MS; Caskurlu T; Yildirim A
    Urol Res Pract; 2023 Jul; 49(4):253-258. PubMed ID: 37877827
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A review on lymphocyte radiosensitivity and its impact on radiotherapy.
    Paganetti H
    Front Oncol; 2023; 13():1201500. PubMed ID: 37601664
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.